ATE282708T1 - Herpes-virusstämme für die gentherapie - Google Patents

Herpes-virusstämme für die gentherapie

Info

Publication number
ATE282708T1
ATE282708T1 AT01901288T AT01901288T ATE282708T1 AT E282708 T1 ATE282708 T1 AT E282708T1 AT 01901288 T AT01901288 T AT 01901288T AT 01901288 T AT01901288 T AT 01901288T AT E282708 T1 ATE282708 T1 AT E282708T1
Authority
AT
Austria
Prior art keywords
hsv1
strain
hsv
gene therapy
herpes virus
Prior art date
Application number
AT01901288T
Other languages
English (en)
Inventor
Robert Stuart Coffin
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27447756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE282708(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0001475A external-priority patent/GB0001475D0/en
Priority claimed from GB0002854A external-priority patent/GB0002854D0/en
Priority claimed from GB0100288A external-priority patent/GB0100288D0/en
Priority claimed from GB0100430A external-priority patent/GB0100430D0/en
Application filed by Biovex Ltd filed Critical Biovex Ltd
Application granted granted Critical
Publication of ATE282708T1 publication Critical patent/ATE282708T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AT01901288T 2000-01-21 2001-01-22 Herpes-virusstämme für die gentherapie ATE282708T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0001475A GB0001475D0 (en) 2000-01-21 2000-01-21 Virus strains
GB0002854A GB0002854D0 (en) 2000-02-08 2000-02-08 Virus strains
GB0100288A GB0100288D0 (en) 2001-01-05 2001-01-05 Virus strains
GB0100430A GB0100430D0 (en) 2001-01-06 2001-01-06 Virus strains
PCT/GB2001/000225 WO2001053505A2 (en) 2000-01-21 2001-01-22 Herpes virus strains for gene therapy

Publications (1)

Publication Number Publication Date
ATE282708T1 true ATE282708T1 (de) 2004-12-15

Family

ID=27447756

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01901292T ATE312189T1 (de) 2000-01-21 2001-01-22 Virusstämme für die onkolytische behandlung von krebs
AT01901288T ATE282708T1 (de) 2000-01-21 2001-01-22 Herpes-virusstämme für die gentherapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01901292T ATE312189T1 (de) 2000-01-21 2001-01-22 Virusstämme für die onkolytische behandlung von krebs

Country Status (22)

Country Link
US (12) US7223593B2 (de)
EP (4) EP1568779A1 (de)
JP (6) JP4810042B2 (de)
KR (2) KR100802403B1 (de)
CN (2) CN1418255A (de)
AT (2) ATE312189T1 (de)
AU (2) AU2695101A (de)
BE (1) BE2016C033I2 (de)
BR (3) BRPI0107736B8 (de)
CA (2) CA2398343A1 (de)
CY (2) CY2016021I2 (de)
DE (2) DE60115600T2 (de)
DK (2) DK1252322T4 (de)
ES (2) ES2233600T5 (de)
FR (1) FR16C0026I2 (de)
GB (2) GB2374873C (de)
HK (2) HK1047451B (de)
IL (4) IL150677A0 (de)
LU (2) LU93101I2 (de)
NL (2) NL300820I2 (de)
PT (1) PT1252322E (de)
WO (2) WO2001053505A2 (de)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
BRPI0107736B8 (pt) * 2000-01-21 2021-05-25 Biovex Ltd cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1
AU2002306919B2 (en) 2001-03-27 2007-11-22 Tomoki Todo Viral vectors and their use in therapeutic methods
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
JP2007511216A (ja) * 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
AU2005228788B2 (en) * 2004-03-31 2010-12-02 Tomoki Todo Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment
JP4903689B2 (ja) * 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
US10000757B2 (en) * 2005-05-27 2018-06-19 Ospedale San Raffaele S.R.L. Gene vector
US20080008686A1 (en) * 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
CN102666843B (zh) 2009-12-21 2014-10-22 布里格海姆妇女医院公司 单纯疱疹病毒疫苗
CN102146418B (zh) * 2010-02-09 2014-01-15 武汉滨会生物科技有限公司 重组ⅱ型单纯疱疹病毒载体及其制备方法、重组病毒、药物组合物及应用
WO2011101912A1 (ja) * 2010-02-19 2011-08-25 国立大学法人東京大学 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物
EP2550298B1 (de) 2010-03-23 2015-07-15 The Regents of The University of California Zusammensetzungen und verfahren für selbsttragende impfstoffe gegen mikroben und tumore
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
ES2704632T3 (es) * 2011-09-08 2019-03-19 Univ New York Virus de herpes simplex oncolítico y sus usos terapéuticos
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
EP3473708B1 (de) 2012-07-24 2021-01-27 The General Hospital Corporation Onkolytische virustherapie für resistente tumore
EP3981791A1 (de) * 2012-08-30 2022-04-13 Amgen Inc. Verfahren zur behandlung eines melanoms mittels herpes-simplex-virus und immun-checkpoint-inhibitor
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
RU2020105656A (ru) * 2013-07-17 2021-01-27 Юниверсити Оф Питтсбург- Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Нетоксичные векторы на основе впг для применений в эффективной доставке генов и комплементирующие клетки для их продуцирования
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
ES2744837T3 (es) 2013-10-24 2020-02-26 Amgen Inc Inyector y procedimiento de ensamblaje
CA3183645A1 (en) 2013-10-25 2015-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
US20160303174A1 (en) 2013-12-11 2016-10-20 The General Hospital Corporation Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
KR102496507B1 (ko) 2014-05-07 2023-02-03 암겐 인코포레이티드 충격 감소 요소들을 가진 자동 주사기
IL297356A (en) 2014-06-03 2022-12-01 Amgen Inc Controllable drug delivery system and method of use
CA2957960C (en) 2014-10-14 2023-08-22 Amgen, Inc. Drug injection device with visual and audible indicators
JP6625627B2 (ja) 2014-10-14 2019-12-25 ハロザイム インコーポレイテッド アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
FI3250550T3 (fi) 2015-01-26 2023-07-17 Ottawa Hospital Res Inst Koostumuksia ja menetelmiä virusherkistymiseen
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (de) 2015-02-27 2022-04-13 Amgen, Inc Arzneimittelabgabevorrichtung mit nadelschutzmechanismus mit abstimmbarem widerstandsschwellwert gegenüber der bewegung des nadelschutzes
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
WO2016168601A1 (en) 2015-04-17 2016-10-20 Khalid Shah Agents, systems and methods for treating cancer
WO2016174200A1 (en) 2015-04-30 2016-11-03 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
CN105219738A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
WO2017103291A1 (en) 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Virus encoding an anti-tcr-complex antibody or fragment
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
JP7038664B2 (ja) 2016-01-08 2022-03-18 レプリミュン リミテッド 操作された腫瘍溶解性ウイルス
CN109414487B (zh) 2016-02-19 2022-09-02 复诺健生物科技加拿大有限公司 利用stat1/3抑制剂与溶瘤型疱疹病毒的组合物和方法
ES2814287T3 (es) 2016-03-15 2021-03-26 Amgen Inc Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
EP4212169A1 (de) 2016-03-25 2023-07-19 PeriphaGen, Inc. Hochumwandelnde hsv-vektoren
KR20230051601A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
EP3426272A4 (de) 2016-04-26 2020-03-04 Salk Institute for Biological Studies Onkolytische hsv-1-virustherapien mit spezifischer tötung alt-abhängiger karzinome
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
CN115960966A (zh) 2016-04-29 2023-04-14 复诺健生物科技加拿大有限公司 在癌细胞中具有增强复制的hsv载体
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
CA3018426A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
CA3032120A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018026872A1 (en) 2016-08-01 2018-02-08 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
SI3518948T1 (sl) 2016-10-03 2023-09-29 Ottawa Hospital Research Institute Kompozicije in metode za povečanje rasti, širjenja ter onkolitične in imunoterapevtske učinkovitosti onkolitičnih RNA-virusov
WO2018075447A1 (en) 2016-10-19 2018-04-26 The Trustees Of Columbia University In The City Of New York Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
EP3872180A1 (de) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Sekretierbare variante immunmodulatorische proteine und manipulierte zelltherapie
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
AU2017379835A1 (en) 2016-12-21 2019-07-11 Dnatrix Armed replication-competent oncolytic adenoviruses
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
EP3580341A4 (de) 2017-02-09 2020-11-04 Indapta Therapeutics, Inc. Manipulierte natürliche killer(nk)-zellen und zusammensetzungen und verfahren dafür
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
MX2019010797A (es) 2017-03-15 2019-10-24 Amgen Inc Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer.
AU2018235835A1 (en) 2017-03-16 2019-09-05 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
DK3596116T3 (da) 2017-03-16 2023-11-27 Alpine Immune Sciences Inc Variante immunmodulatoriske pd-l1-proteiner og anvendelser deraf
BR112019018747A2 (pt) 2017-03-16 2020-05-05 Alpine Immune Sciences Inc proteínas imunomoduladoras variantes de cd80 e usos das mesmas
FI3600491T3 (fi) 2017-03-28 2023-10-20 Amgen Inc Männänvarren ja ruiskukokoonpanon järjestelmä ja menetelmä
US20210008135A1 (en) 2017-04-28 2021-01-14 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
CN106974942A (zh) * 2017-05-03 2017-07-25 武汉滨会生物科技股份有限公司 重组溶瘤ii型单纯疱疹病毒在制备抗淋巴瘤、食道癌、乳腺癌、胰腺癌药物中的应用
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CN107354136A (zh) * 2017-06-15 2017-11-17 杭州睿可特生物科技有限公司 重组单纯疱疹病毒及其制备方法和应用
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
JP2020527376A (ja) 2017-07-21 2020-09-10 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
EP3658203B1 (de) 2017-07-25 2022-08-31 Amgen Inc. Arzneimittelabgabevorrichtung mit getriebemodul und verwandtes verfahren zur montage
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
HUE058233T2 (hu) 2017-08-03 2022-07-28 Amgen Inc Interleukin-21-muteinek és kezelési eljárások
AU2018314227A1 (en) 2017-08-07 2020-02-06 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
EP3668567A1 (de) 2017-08-18 2020-06-24 Amgen Inc. Am körper tragbarer injektor mit sterilem klebepflaster
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
EP3681998A1 (de) 2017-09-11 2020-07-22 IMBA-Institut für Molekulare Biotechnologie GmbH Tumororganoidmodell
EP3691717B1 (de) 2017-10-04 2023-02-08 Amgen Inc. Durchflussadapter für arzneimittelabgabevorrichtung
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
AU2018351000B2 (en) 2017-10-18 2023-11-30 Alpine Immune Sciences, Inc. Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
WO2019084418A1 (en) 2017-10-27 2019-05-02 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
CN111278487B (zh) 2017-11-16 2022-06-24 安进公司 用于药物递送装置的门闩锁机构
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CR20200330A (es) 2018-01-12 2020-12-23 Amgen Inc Anticuerpos anti-pd-1 y métodos de tratamiento
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2019185828A1 (en) * 2018-03-28 2019-10-03 Bioxodes Anticoagulant fusion proteins and uses thereof
CA3098572A1 (en) * 2018-05-01 2019-11-07 Albert Einstein College Of Medicine Hsv-2-delta-gd vaccines and methods for their production and use
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
JP7379385B2 (ja) 2018-06-04 2023-11-14 カリディ・バイオセラピューティクス・インコーポレイテッド ウイルス療法を増強するための細胞ベースの媒体
EP3801583A1 (de) 2018-06-08 2021-04-14 The Board of Trustees of the University of Illinois Rekombinantes herpes-simplex-virus zur krebsimmuntherapie
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
EP3807304A1 (de) * 2018-06-15 2021-04-21 Children's Hospital Medical Center Polypeptide, nukleinsäuremoleküle, zusammensetzungen und zugehörige verfahren
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
CN112351804A (zh) 2018-07-24 2021-02-09 安进公司 用于施用药物的输送装置
US20210228815A1 (en) 2018-07-24 2021-07-29 Amgen Inc. Hybrid drug delivery devices with grip portion
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
AU2019350660A1 (en) 2018-09-28 2021-03-18 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
CA3112214A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
CN112689523A (zh) 2018-10-15 2021-04-20 安进公司 用于药物递送装置的平台组装方法
EA202191037A1 (ru) 2018-10-15 2021-08-05 Эмджен Инк. Устройство доставки лекарственного средства, имеющее демпферный механизм
US20220031953A1 (en) 2018-11-01 2022-02-03 Amgen Inc. Drug delivery devices with partial needle retraction
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
EP3873566A1 (de) 2018-11-01 2021-09-08 Amgen Inc. Vorrichtung zur verabreichung von medikamenten mit teilweisem rückzug des medikamentenabgabeelements
AU2019377141A1 (en) 2018-11-06 2021-05-20 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
WO2020107002A2 (en) 2018-11-21 2020-05-28 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
JP2022510276A (ja) 2018-11-30 2022-01-26 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
TW202039835A (zh) 2018-12-27 2020-11-01 美商安進公司 凍乾病毒配製物
CN113748124A (zh) 2019-02-27 2021-12-03 阿克蒂姆治疗有限公司 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌
JP2022522817A (ja) * 2019-03-05 2022-04-20 アムジエン・インコーポレーテツド がんを治療するための腫瘍溶解性ウイルスの使用
EP3938524A1 (de) * 2019-03-14 2022-01-19 Massachusetts Institute of Technology Manipulierte herpes-simplex-virus-1 (hsv-1)-vektoren und ihre verwendungen
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
JP2022529319A (ja) 2019-04-24 2022-06-21 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
AU2020337250A1 (en) 2019-08-23 2022-03-03 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021127524A1 (en) * 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
AU2021258194A1 (en) 2020-04-22 2022-11-24 Indapta Therapeutics, Inc. Natural killer (NK) cell compositions and methods for generating same
WO2022015407A1 (en) * 2020-07-16 2022-01-20 Massachusetts Institute Of Technology Simultaneous delivery of cancer treatment programs to tumor and immune cells
TW202241479A (zh) 2020-12-30 2022-11-01 美商安迅生物製藥公司 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法
EP4288140A1 (de) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvante therapie für krebs
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
TW202313982A (zh) * 2021-08-20 2023-04-01 大陸商廣東東陽光藥業有限公司 Hsv病毒載體及其應用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5163949A (en) * 1990-03-02 1992-11-17 Bonutti Peter M Fluid operated retractors
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
GB9202933D0 (en) 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
DK0675961T3 (da) 1992-03-31 2003-03-24 Arch Dev Corp Behandling af tumorigen sygdom med en modificeret HSV
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9423663D0 (en) * 1994-11-23 1995-01-11 Cantab Pharma Res Viral preparations, immunogens, and vaccines
NL9500216A (nl) * 1995-02-06 1996-09-02 Bio Pharma Sciences Bv Farmaceutische samenstelling voor de behandeling van herpes.
DE69636068T2 (de) * 1995-02-21 2006-11-30 Cantab Pharmaceuticals Research Ltd. Virale zubereitungen, vektoren, immunogene und impfstoffe
IL118942A (en) 1995-07-27 2002-09-12 American Cyanamid Co Nonviolent viruses used as killers - tumors and vaccines
US6344445B1 (en) * 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
GB2322130B (en) 1997-02-13 2000-12-20 Secr Defence A vaccine against Simian Herpes B virus
GB9704046D0 (en) * 1997-02-27 1997-04-16 Univ Leeds Arrestable therapeutic
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
WO1999045783A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
GB9810904D0 (en) 1998-05-20 1998-07-22 Univ London Mutant herpes simplex viruses and uses thereof
US6713067B2 (en) 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
EP1102790B1 (de) 1998-08-07 2014-05-07 University of Washington Immunologische Herpes Simplex Virus Antigene und Verfahren für deren Verwendung
EP1141338A4 (de) * 1998-12-31 2002-09-25 Arch Dev Corp Rekombinantes herpes simplex virus zur behandlung von neoplastischen erkrankungen
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
WO2000075292A1 (en) 1999-06-08 2000-12-14 Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
IL131212A0 (en) * 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
GB9930419D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
BRPI0107736B8 (pt) 2000-01-21 2021-05-25 Biovex Ltd cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1
GB0001476D0 (en) 2000-01-21 2000-03-15 Neurovex Ltd Herpes virus strains
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
JP7038664B2 (ja) * 2016-01-08 2022-03-18 レプリミュン リミテッド 操作された腫瘍溶解性ウイルス

Also Published As

Publication number Publication date
FR16C0026I1 (de) 2016-07-22
US8680068B2 (en) 2014-03-25
GB2375113A (en) 2002-11-06
CA2398335C (en) 2010-12-07
WO2001053506A3 (en) 2002-05-23
HK1047297B (zh) 2004-10-21
GB2374873C (en) 2011-07-27
CY2016021I1 (el) 2016-12-14
CN1250732C (zh) 2006-04-12
CY2016020I2 (el) 2016-12-14
EP1252323A2 (de) 2002-10-30
AU2694701A (en) 2001-07-31
EP2177619A1 (de) 2010-04-21
DE60115600D1 (de) 2006-01-12
BR0107736A (pt) 2002-11-19
FR16C0026I2 (fr) 2018-04-27
US20090220460A1 (en) 2009-09-03
ATE312189T1 (de) 2005-12-15
US20150232812A1 (en) 2015-08-20
BRPI0107737B1 (pt) 2016-11-16
ES2233600T3 (es) 2005-06-16
US10301600B2 (en) 2019-05-28
DK1252323T3 (da) 2006-04-03
US20070003571A1 (en) 2007-01-04
IL150678A (en) 2008-12-29
EP1252322B1 (de) 2004-11-17
JP6424145B2 (ja) 2018-11-14
JP4810042B2 (ja) 2011-11-09
IL150677A (en) 2008-12-29
CN1418255A (zh) 2003-05-14
JP2017132779A (ja) 2017-08-03
CA2398343A1 (en) 2001-07-26
NL300820I2 (de) 2016-11-17
AU2001226951B2 (en) 2006-10-05
BR0107737A (pt) 2002-11-19
DE60107203T2 (de) 2005-12-01
BRPI0107736B8 (pt) 2021-05-25
GB2374873B (en) 2004-05-26
CY2016020I1 (el) 2016-12-14
JP2019048864A (ja) 2019-03-28
IL150677A0 (en) 2003-02-12
DE60107203D1 (de) 2004-12-23
HK1047297A1 (en) 2003-02-14
JP4921669B2 (ja) 2012-04-25
US20030091537A1 (en) 2003-05-15
CN1425073A (zh) 2003-06-18
US20140154216A1 (en) 2014-06-05
WO2001053505A2 (en) 2001-07-26
DE60107203T3 (de) 2009-07-23
US20070264282A1 (en) 2007-11-15
DK1252322T4 (da) 2009-06-08
LU93101I2 (fr) 2016-08-08
US20200032219A1 (en) 2020-01-30
JP2003520789A (ja) 2003-07-08
IL150678A0 (en) 2003-02-12
KR100768408B1 (ko) 2007-10-18
WO2001053505A3 (en) 2001-12-27
JP2003520044A (ja) 2003-07-02
US20030113348A1 (en) 2003-06-19
US7223593B2 (en) 2007-05-29
US7063835B2 (en) 2006-06-20
AU2695101A (en) 2001-07-31
US20200032218A1 (en) 2020-01-30
CY2016021I2 (el) 2016-12-14
BRPI0107737B8 (pt) 2021-05-25
JP2015221813A (ja) 2015-12-10
EP1568779A1 (de) 2005-08-31
BE2016C033I2 (de) 2020-05-20
ES2233600T5 (es) 2009-06-22
GB2375113B (en) 2004-10-20
GB0219033D0 (en) 2002-09-25
US20120321599A1 (en) 2012-12-20
GB0219030D0 (en) 2002-09-25
WO2001053506A2 (en) 2001-07-26
US20140154215A1 (en) 2014-06-05
AU2001226951B8 (en) 2006-10-26
JP2012072156A (ja) 2012-04-12
EP1252322B2 (de) 2009-03-04
NL300821I2 (de) 2016-10-27
EP1252322A2 (de) 2002-10-30
CA2398335A1 (en) 2001-07-26
HK1047451B (zh) 2005-03-18
ES2254359T3 (es) 2006-06-16
US8277818B2 (en) 2012-10-02
GB2374873A (en) 2002-10-30
DE60115600T2 (de) 2006-07-20
US20120164108A1 (en) 2012-06-28
DK1252322T3 (da) 2005-03-14
PT1252322E (pt) 2005-03-31
US7537924B2 (en) 2009-05-26
KR20020080383A (ko) 2002-10-23
LU93100I2 (fr) 2016-08-08
BRPI0107736B1 (pt) 2019-12-17
KR20030032913A (ko) 2003-04-26
EP1252323B1 (de) 2005-12-07
AU782659B2 (en) 2005-08-18
HK1047451A1 (en) 2003-02-21
KR100802403B1 (ko) 2008-02-13
JP6644378B2 (ja) 2020-02-12

Similar Documents

Publication Publication Date Title
ATE282708T1 (de) Herpes-virusstämme für die gentherapie
BR9912671A (pt) Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
BR9712366A (pt) Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
CA2361892A1 (en) Treatment of tumors with genetically engineered herpes virus
EP1778186A4 (de) Verfahren zur herstellung von poly-iclc und seine verwendung
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
BR9910594A (pt) Vìrus de herpes simplex, uso de um vìrus de herpessimplex, composição farmacêutica e processospara estudar a função de um gene heterólogo emuma célula de mamìfero, para produzir um vìrus deherpes simplex e para tratar um distúrbio ou uma lesãodo sistema nervoso de um mamìfero
EP1550449A4 (de) Antitumorale mittel mit hsv
AR025203A1 (es) Nuevos genes de mixoma para modulacion inmunitaria
WO2023183528A3 (en) Compositions including ifne and uses thereof
AU6301398A (en) Arrestable therapeutic viral agent
DE60023915D1 (de) Replikationsprotein-a-bindendes transkriptionsfaktor (rbt1) und dessen verwendungen
WO2003047634A3 (en) Nucleic acids and methods for treating ebv-positive cancers

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1252322

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1252322

Country of ref document: EP